Every Form 4 that Regeneron Pharmaceuticals Inc (REGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow REGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full REGN filings page.
REGENERON PHARMACEUTICALS, INC. (REGN) executive vice president of Commercial, Marion McCourt, reported open-market sales of company common stock under a Rule 10b5-1 trading plan. On September 3, 2026, she sold 1,131 shares at $857.39 per share, and on September 2, 2026, she sold 1,215 shares at $850.00 per share. A separate entry reports 219 shares of common stock held indirectly through a 401(k) plan as of September 2, 2026.
REGENERON PHARMACEUTICALS, INC. (REGN) director Kathryn Guarini reported option-related transactions in the company’s stock. On September 2, 2026, she exercised options for 400 shares at an exercise price of $719.37 per share and sold 400 shares at $850.00 per share, under a Rule 10b5-1(c) trading plan adopted on February 13, 2026. Following the option exercise, she continued to hold options covering 1,158 shares of common stock.
REGENERON PHARMACEUTICALS, INC. (REGN) reported insider equity transactions by Joseph J. LaRosa, EVP General Counsel and Secretary. On 2026-08-19, he exercised a non-qualified stock option for 12,282 shares of common stock at an exercise price of $381.92 per share, from an award that vested in four equal annual installments commencing one year after grant. He acquired 12,282 common shares upon exercise and 9,019 shares of common stock at $830.15 per share were delivered or withheld for payment of exercise price or tax liability. Following the transaction, he directly held 12,283 non-qualified stock options expiring on 2026-12-16 and indirect common stock holdings of 3,402 shares via a 2024 GRAT, 5,407 shares via a 2025 GRAT, and 413 shares through a 401(k) plan.
REGENERON PHARMACEUTICALS, INC. (REGN) reported that EVP Finance and CFO Christopher R. Fenimore exercised a non-qualified stock option for 6,283 shares of common stock on 2026-08-18 at an exercise price of $381.92 per share. The stock option award vested in four equal annual installments. In connection with the exercise, 4,599 shares of common stock were delivered or withheld at $813.47 per share for payment of the exercise price or tax liability. Following the transaction, Fenimore had 6,000 stock options remaining from this grant and held additional shares indirectly through a 401(k) plan and several trusts.
REGENERON PHARMACEUTICALS, INC. director Kathryn Guarini exercised 400 non-qualified stock options for Common Stock at an exercise price of $719.37 per share on August 10, 2026, leaving 1,558 options outstanding that expire on January 2, 2035.
The 400 acquired shares were then sold at $800.00 per share the same day. The disposition and acquisition were made pursuant to a Rule 10b5-1(c) trading plan adopted on February 13, 2026.
REGENERON PHARMACEUTICALS, INC. director Huda Y. Zoghbi reported an option exercise-and-sale on August 10, 2026. She exercised 800 Non‑Qualified Stock Options for 800 shares of Common Stock at an exercise price of $376.6900 per share, fully exhausting this option grant, and then sold the 800 acquired shares. All transactions were made under a Rule 10b5‑1(c) trading plan adopted on November 20, 2025.
REGENERON PHARMACEUTICALS, INC. director Arthur F. Ryan reported an open-market sale of 200 shares of common stock on July 2, 2026 at a volume-weighted average price of $650.15 per share. The trade was executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on October 31, 2025, indicating it was scheduled in advance. Following this transaction, Ryan directly holds 17,303 shares of Regeneron common stock.
Regeneron Pharmaceuticals director Arthur F. Ryan reported selling 100 shares of the company’s common stock in multiple open-market trades on May 1, 2026. The shares were sold at prices generally between about $701 and $714 per share under a pre-arranged Rule 10b5-1(c) trading plan adopted on October 31, 2025. After these planned sales, he continues to hold a direct equity stake in the company.
Regeneron Pharmaceuticals director Arthur F. Ryan sold 100 shares of Common Stock in open-market transactions. The sales occurred on April 1, 2026 at prices ranging from about $771.32 to $779.71, executed in multiple small tranches using volume-weighted average prices.
The filing states these dispositions were made under a pre-arranged trading plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. Following the transactions, Ryan directly holds 17,603 Common Stock shares of Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals director Arthur F. Ryan sold 100 shares of common stock in a series of open-market transactions on March 2, 2026 under a Rule 10b5-1(c) trading plan adopted on October 31, 2025. The shares were sold at volume-weighted average prices ranging from $777.08 to $789.37 per share. After these sales, Ryan directly owned 17,703 Regeneron shares.
REGENERON PHARMACEUTICALS, INC. director Huda Y. Zoghbi reported option exercises and related share sales. On February 19, 2026, Zoghbi exercised a non-qualified stock option for 1,638 shares at an exercise price of $0.00, receiving 1,638 shares of common stock at $376.69 per share.
The same day, Zoghbi executed multiple open-market sales totaling 1,638 common shares at prices generally in the high-$770s to around $790 per share, pursuant to a Rule 10b5-1(c) trading plan adopted on November 20, 2025. After these transactions, Zoghbi held 1,703 Regeneron common shares directly.
Pitofsky Jason reported multiple insider transaction types in a Form 4 filing for REGN. The filing lists transactions totaling 4,036 shares at a weighted average price of $684.14 per share. Following the reported transactions, holdings were 4,272 shares.
Regeneron Pharmaceuticals director Arthur F. Ryan reported selling 100 shares of the company’s common stock on February 9, 2026 in a series of small open-market trades. Reported sale prices ranged from about $775.63 to $787.82 per share.
The filing states these transactions were made under a Rule 10b5-1(c) trading plan adopted on October 31, 2025, which pre-schedules trades. Following the transactions, Ryan directly beneficially owned 17,803 shares of Regeneron common stock.
Regeneron Pharmaceuticals director Bonnie L. Bassler reported an option exercise and share sale. On January 7, 2026, she exercised 1,500 Non-Qualified Stock Options with an exercise price of $374.12 per share, receiving 1,500 shares of common stock. That same day, she sold 1,500 common shares at a volume-weighted average price of $800.00 per share under a Rule 10b5-1(c) trading plan adopted on May 2, 2025. After these transactions, she directly held 1,703 shares of common stock and 2,861 stock options.
Regeneron Pharmaceuticals director Craig B. Thompson reported new equity awards. On January 2, 2026, he acquired 155 time-based restricted stock units, each representing one share of Regeneron common stock, and 1,962 non-qualified stock options with a conversion (exercise) price of $772.76 per share.
After these grants, Thompson directly beneficially owned 775 shares of common stock and 1,962 stock options. A portion of the options will become exercisable on the date of Regeneron’s first annual shareholder meeting following the grant, in proportion to the part of a year that has elapsed since grant, with the remaining options becoming exercisable on the first anniversary of the grant date.
Regeneron Pharmaceuticals director George L. Sing reported new equity awards in company stock. On January 2, 2026, he acquired 155 shares of common stock at a price of $0.0 per share, described as time-based vesting restricted stock units that each represent a right to receive one share of common stock. On the same date, he received a non-qualified stock option to buy 1,962 shares of common stock at an exercise price of $772.76 per share, expiring on January 2, 2036.
Following these awards, Sing directly beneficially owns 31,007 shares of Regeneron common stock. Additional indirect holdings reported include 750 shares by his spouse, 400 shares by his spouse as custodian for their son, and 1,000 shares held in a trust for their son. A portion of the stock options becomes exercisable on the date of the first annual shareholder meeting following the grant, with the remainder exercisable on the first anniversary of the grant date.
Regeneron Pharmaceuticals director David P. Schenkein reported new equity awards. On 01/02/2026, he acquired 1,962 non-qualified stock options with an exercise price of $772.76 per share, each option linked to Regeneron common stock. A portion of these options becomes exercisable on the date of the company’s first annual shareholder meeting following the grant, with the remainder vesting on the first anniversary of the grant date.
He also acquired 155 time-based restricted stock units, each representing a contingent right to receive one share of Regeneron common stock. Following this grant, he beneficially owned 603 shares of common stock directly.
Regeneron Pharmaceuticals director Joseph L. Goldstein reported new equity awards. On 01/02/2026, he was granted 1,962 non-qualified stock options with an exercise price of $772.76 per share, each option linked to one share of common stock. A footnote explains that part of these options becomes exercisable on the date of the company’s first annual shareholder meeting following the grant, with the remainder vesting on the first anniversary of the grant date. He also acquired 155 time-based vesting restricted stock units, each representing a contingent right to receive one share of common stock at no purchase price. Following these transactions, he directly beneficially owned 1,962 stock options and 6,703 shares of common stock.
Regeneron Pharmaceuticals director Michael S. Brown reported new equity awards. On January 2, 2026, he received 155 time-based restricted stock units, each representing one share of Regeneron common stock, bringing his directly held common stock to 1,703 shares. He was also granted a non-qualified stock option for 1,962 shares with an exercise price of $772.76 per share, expiring on January 2, 2036; a portion becomes exercisable on the date of the first annual shareholder meeting after the grant, with the remainder on the first anniversary of the grant date.
In addition, the filing lists 5,000 shares held indirectly by a SLAT and 6,162 shares held indirectly by a trust. The trust is for the benefit of Brown’s immediate family, his spouse is trustee, and he disclaims beneficial ownership of those trust-held securities.
Regeneron Pharmaceuticals, Inc. reported an insider stock transaction by executive Daniel P. Van Plew, EVP & General Mgr, Industrial.
On 12/09/2025, he reported a transaction coded F involving the disposition of 2,552 shares of common stock at $701.51 per share. After this, he reported beneficial ownership of 21,673 shares held directly, 12,376 shares held indirectly through a 2025 GRAT, and 1,129 shares held through a 401(k) plan.
Regeneron Pharmaceuticals, Inc. reported an insider stock transaction by an officer serving as EVP Research. On 12/09/2025, the executive disposed of 4,229 shares of common stock at $701.51 per share in a transaction coded "F".
Following this activity, the officer beneficially owned 47,833 shares of Regeneron common stock directly and 4,375 shares indirectly through a 401(k) plan.
Regeneron Pharmaceuticals’ VP Controller reported new equity awards and related share movements. On December 5, 2025, the officer received 2,064 shares of common stock at $0.0 per share as restricted stock under the Second Amended and Restated 2014 Long-Term Incentive Plan, vesting 50% on December 5, 2027 and 50% on December 5, 2029. The same day, the officer was granted a non-qualified stock option for 2,261 shares of common stock with an exercise price of $726.71 per share, expiring on December 5, 2035 and vesting in four equal annual installments beginning one year after the grant date.
On December 8, 2025, the filing shows a disposition of 989 shares of common stock at $712.94 per share. Following these transactions, the officer directly owns 5,308 common shares, with additional indirect holdings of 31 shares through a 401(k) plan and 179 shares held by a spouse, along with the 2,261 stock options.
Regeneron Pharmaceuticals (REGN) executive Joseph LaRosa reported a stock option exercise and share transactions. On 11/20/2025, he exercised a non-qualified stock option for 14,450 shares of common stock at an exercise price of $555.67 per share. On the same date, 12,686 shares were disposed of in a transaction reported at $736.77 per share, which is typically associated with covering taxes or similar obligations.
Following these transactions, LaRosa directly beneficially owned 22,839 shares of Regeneron common stock. He also indirectly owned 9,000 shares through a 2024 GRAT, 9,000 shares through a 2025 GRAT, and 395 shares through a 401(k) plan. The option award referenced in the filing vested in four equal annual installments starting one year after the grant date and is now fully exercised, with zero derivative securities remaining from this grant.
Regeneron Pharmaceuticals (REGN) director reports stock option exercise and sale. On 11/20/2025, the reporting person exercised a non-qualified stock option for 760 shares of common stock at an exercise price of $371.4 per share and then sold 760 shares of common stock at a price of $750 per share. After these transactions, the director beneficially owned 1,548 shares of Regeneron common stock directly and 756 non-qualified stock options. The transactions were made under a Rule 10b5-1(c) trading plan adopted on May 2, 2025.
Regeneron Pharmaceuticals (REGN) reported an insider transaction on Form 4. The company’s VP Controller sold 431 shares of common stock at $651.43 per share on 11/07/2025 (transaction code S). Following the sale, the reporting person beneficially owns 4,233 shares directly, plus 31 shares held by a 401(k) plan and 179 shares held by a trust. This filing documents a routine change in personal holdings and does not alter the company’s capital structure.
Regeneron Pharmaceuticals (REGN) director Christine A. Poon reported insider transactions. On 10/29/2025, she exercised 6,500 non-qualified stock options at $520.01 and sold shares in multiple trades: 650 at $652.68, 2,735 at $653.5, 1,915 at $654.42, 100 at $655.1, 712 at $656.5, and 388 at $657.29.
On 10/30/2025, she exercised an additional 2,712 options at $520.01. Following the reported transactions, she beneficially owned 5,064 shares, held directly.
Regeneron Pharmaceuticals (REGN) executive Andrew Murphy reported insider transactions. On 10/29/2025, he exercised 35,000 non‑qualified stock options at $555.67 per share (code M), acquiring common stock. To cover taxes, 32,490 shares were withheld at $648.82 (code F). On 10/30/2025, he made a bona fide gift of 1,538 shares (code G).
After these transactions, he beneficially owned 50,046 shares directly and 4,370 shares indirectly via a 401(k) plan. The exercised option, which was scheduled to expire on 12/16/2025 and vested in four annual installments, now has 0 remaining.